Anti-alpha 1a Adrenergic Receptor/ADRA1A antibody [EPR9691(B)]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

The alpha 1a Adrenergic Receptor also known as ADRA1A or alpha 1a receptor is a type of G protein-coupled receptor with an approximate mass of 56 kDa. It is a part of the adrenergic receptors family which are known for responding to adrenaline and noradrenaline. This receptor is expressed predominantly in smooth muscle tissues such as those in the prostate and blood vessels. Mechanically the A1 adrenergic receptor activates phospholipase C via Gq proteins leading to an increase in intracellular calcium levels.

Biological function summary

Alpha 1a Adrenergic Receptor plays a critical role in regulating smooth muscle contraction and blood vessel vasoconstriction. It forms an important part of the adrenergic receptor system which also includes alpha adrenergic receptors such as alpha 1b and alpha 1d subclasses. The activation of the alpha 1a receptor promotes vasoconstriction which contributes to blood pressure regulation. Additionally it is involved in modulating neurotransmitter release through its presence in nerve cells.

Pathways

Alpha 1a Adrenergic Receptor figures prominently in signaling pathways that manage cardiovascular functions. It is tightly associated with the GPCR signaling pathway which includes other adrenergic receptors and proteins like beta adrenergic receptors. Another significant pathway is the calcium signaling pathway where its impact on intracellular calcium plays a role in muscle contractions linking it to other proteins involved in the contraction machinery.

Associated diseases and disorders

Alpha 1a Adrenergic Receptor connects to conditions such as hypertension and benign prostatic hyperplasia (BPH). The receptor’s role in vasoconstriction directly links to hypertension where it affects arterial blood pressure. In BPH the alpha 1a receptor influences prostate smooth muscle tone making it a target in treating urinary symptoms. These conditions involve proteins like angiotensin-converting enzyme in hypertension and other alpha receptors in BPH highlighting the ADRA1A's importance in therapeutic strategies.